AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02179788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~* Days 1-7, take 1 capsule with evening meal~* Days 8-14, take 3 capsules with evening meal~* Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.
Trial: NCT01865331
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin)
Trial: NCT01287351
Drug: extra-fine hydrofluoroalkane beclometasone dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00095537
Drug: panHer
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
Trial: NCT03334695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as sterile 0.9% saline for injection.
Trial: NCT01994980
Drug: Default 4 days antibiotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
Trial: NCT00065962
Drug: secretin, synthetic porcine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02625974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00840840
Drug: Augmentin ES-600™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 600 mg/42.9 mg/5 mL, single-dose fasting
Trial: NCT01253564
Drug: RO5185426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960 mg b.i.d. orally
Trial: NCT02990910
Drug: Individualized opioid analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
Trial: NCT00657527
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01315678
Drug: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.
Trial: NCT01315678
Drug: Tobramycin inhalation solution using a PARI LC® Plus nebulizer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~* Nebulization time is approximately 20 minutes for each administration.~* Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment
Trial: NCT00368576
Drug: SB 480848, tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01872988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer Placebo to HCC patients who are indicated for TACE after randomization
Trial: NCT00364559
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg 10 days daily
Trial: NCT02509286
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
Trial: NCT00642993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching SCH 497079 administered orally
Trial: NCT03544242
Drug: Pre-Isolation Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
Trial: NCT00413127
Drug: NaCl 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo i.v.
Trial: NCT01993186
Drug: UX007
RxNorm normalized name: UX007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral liquid
Trial: NCT01993186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral liquid
Trial: NCT01513161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00491738
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT05214677
Drug: DW1809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pelubiprofen 30mg
Trial: NCT03608917
Drug: Total Glucosides of Paeony(TGP) analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Glucosides of Paeony(TGP) analogue as a placebo for Control group
Trial: NCT00273377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02910245
Drug: Mercaptopurine (Purinethol)
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04337658
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/m2 orally Bid on day 1 to day 14 every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
Trial: NCT02910245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01975753
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03531060
Drug: IRL790
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRL790 capsule 10 mg
Trial: NCT03531060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT00042380
Drug: Novasoy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00413959
Drug: VELCADE®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
Trial: NCT00413959
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
Trial: NCT02288273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01039675
Drug: 500mcg/25mcg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK573719/GW642444
Trial: NCT01568814
Drug: Low volume PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low volume polyethylene glycol 2 liter one time
Trial: NCT01568814
Drug: high volume PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
Trial: NCT01039675
Drug: Placebo once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive, excipients only
Trial: NCT01617941
Drug: BGG492
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01617941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
Trial: NCT03373604
Drug: 18F-MK-6240
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
Trial: NCT00822744
Drug: Placebo (for SSR411298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: capsule~Route: oral administration with food
Trial: NCT04512404
Drug: HMG-CoA Reductase Inhibitor
RxNorm normalized name: HMG-CoA reductase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02641730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
Trial: NCT01386333
Drug: Saline Nasal Mist
RxNorm normalized name: Saline Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
Trial: NCT02286531
Drug: O-(2[18F]FLUOROETHYL)-L-TYROSINE
RxNorm normalized name: 3-hydroxy-O-phosphono-L-tyrosine
DrugBank: Foslevodopa (DB16683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
Trial: NCT02792816
Drug: First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
Trial: NCT02789150
Drug: Norepinephrine (Levophed)
RxNorm normalized name: norepinephrine Injection [Levophed]
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrate norepinephrine to MAP 65-70
Trial: NCT02789150
Drug: Norepinephrine (Levophed)
RxNorm normalized name: norepinephrine Injection [Levophed]
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrate norepinephrine to MAP 85 or greater
Trial: NCT05122234
Drug: Standard treatment of Covid-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of Covid-19 based on national protocol.
Trial: NCT02790528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug will be administered.
Trial: NCT00030342
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02670083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Trial: NCT02456428
Drug: Insulins
RxNorm normalized name: INSULINS AND ANALOGUES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
Trial: NCT02870582
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best support treatment
Trial: NCT02456428
Drug: Alpha-glucosidase inhibitors
RxNorm normalized name: alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Trial: NCT00150592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03093025
Drug: TS-121 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally taken once daily
Trial: NCT03093025
Drug: TS-121 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally taken once daily
Trial: NCT03093025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally taken once daily
Trial: NCT01438060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
Trial: NCT01218360
Drug: Physician standard-of-care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
Trial: NCT01325740
Drug: STX107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
Trial: NCT01532414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule taken one time daily for 3 months
Trial: NCT04072302
Drug: KAF156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet
Trial: NCT04072302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tablet, 20 mg tablet, 50 mg tablet
Trial: NCT02252016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
Trial: NCT04275349
Drug: Xingnaojing injection within 24 hours of symptom onset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital
Trial: NCT02521701
Drug: NFL101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 1: 100 µg~* 50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~* 100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~* The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL.
Trial: NCT00880815
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03118297
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
Trial: NCT01394445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours~PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg
Trial: NCT01512628
Drug: Pentaspan, voluven, volulyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
Trial: NCT03147053
Drug: Jiedu Tongluo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
Trial: NCT03147053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
Trial: NCT00482612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
Trial: NCT03574805
Drug: PRS-060
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug
Trial: NCT03574805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalant designed to mimic PRS-060
Trial: NCT01956812
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
Trial: NCT00672373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat flour placebo capsule,1 capsule tid, po,12 weeks
Trial: NCT02450487
Drug: Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
Trial: NCT03717701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take inert tablets similar in appearance, color, and consistency
Trial: NCT00991796
Drug: CS-1008
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
Trial: NCT00991796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02108353
Drug: Melatonin 2mg
RxNorm normalized name: Vicks ZzzQuil PURE Zzzs Melatonin 2mg Extended-Release Tablet
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
Trial: NCT02108353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
Trial: NCT03876444
Drug: Intravenous Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Methylprednisolone will be used in the intervention group
Trial: NCT03876444
Drug: Oral Pednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Prednisolone will be used in the Control Group
Trial: NCT03742349
Drug: NIR178
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT01200784
Drug: Nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage
Trial: NCT02278302
Drug: Aggrenox®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02278302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04418219
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
Trial: NCT00684307
Drug: AZD0837
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER tablet, PO, once daily for a period of 3-9 months.
Trial: NCT00684307
Drug: AZD0837
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER tablet, PO, twice daily for a period of 3-9 months
Trial: NCT00272441
Drug: inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06251349
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: postoperative treatment with diclofenac to prevent HO
Trial: NCT01174849
Drug: Prevenar13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium.
Trial: NCT01174849
Drug: COMBO
RxNorm normalized name: Comboguard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
Trial: NCT00275184
Drug: Citramag powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02118688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03178487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00004900
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01285908
Drug: Intravenous Norepinephrine Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00835588
Drug: PROTONIX® 40 mg delayed-release tablets.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 40 mg
Trial: NCT00295490
Drug: Devil Claw
RxNorm normalized name: DEVILS CLAW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose ranging study so will elucidate dose Frequency is four times daily